Cite
HARVARD Citation
Sanchorawala, V. et al. (2022). Health‐related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study. American journal of hematology. 97 (6), pp. 719-730. [Online].